2022年10月22日

特拉維夫,以色列,2022年10月19日——FEMSelect的創造者EnPlace®,微創,無網格方法盆底韌帶固定,今天宣布完成B係列的900萬美元資金。羅賓漢企業、中大西洋生物天使(MABA),梅達天使,集團公司論壇中部,RAD生物醫學,集團公司資本,橫渡太平洋的合資方共同圓。新時代的企業,總部位於紐約,是一個在全球範圍內活躍的風險工作室管理投資醫療、醫療器械,和數字醫療等行業。投資後,新時代公司將加入FEMSelect董事會。TriVentures是一個全球性的醫療風險投資基金總部位於以色列和矽穀,FEMSelect從一開始的融資。FEMSelect女士領導公司的使命是使婦女的健康長期的不同通過提供創新技術,提供一致的結果成規的方式和顯著改善結果。更多信息在EnPlace®係統,請點擊這裏。FDA已清除FEMSelect EnPlace®係統方法對盆底韌帶固定管理症狀性子宮脫垂,並發症影響近50%的50歲以上的婦女。當前程序入侵和經常涉及子宮切除,許多女性都希望避免的。微創手術的技術允許在30分鍾,和臨床研究表明,女性可以在幾天內恢複正常活動。 The Series B Round will support EnPlacegrowth ®’s market penetration, primarily in the United States. The funding follows EnPlacerecent ®’s successful United States and Israel launches. It is supported by positive clinical data on EnPlaceapical ®’s repair success rate of 92.3% at four years, which was published in the peer-reviewed International Journal of Gynecology and Obstetrics. Over the past year, FEMSelect has collaborated with leading women’s healthcare company LiNA Medical USA to educate physicians on the technology. EnPlace® received a procedure code from its Centers for Medicare and Medicaid Services (CMS) earlier this year, allowing healthcare facilities to receive reimbursement for the procedure. EnPlace® is currently present in more then 25 states across the United States.’ Debbie Garner, Co-CEO of FEMSelect: “This investment demonstrates our commitment to our team and the EnPlace® system, allowing us to expand the medical and patient communities and serve many more women seeking a minimally invasive treatment option.” We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know -if there are any discrepancies in any of our published stories, -how we can improve, -what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!